Evogene Ltd. Reports Q2 2025 Financial Results
Ticker: EVGN · Form: 6-K · Filed: Aug 19, 2025 · CIK: 1574565
Sentiment: neutral
Topics: earnings, financial-results, sec-filing
TL;DR
Evogene dropped Q2 2025 earnings on Aug 19th, check the 6-K for details.
AI Summary
Evogene Ltd. announced its financial results for the second quarter ended June 30, 2025, on August 19, 2025. The company filed a Form 6-K report with the SEC to furnish a press release detailing these results.
Why It Matters
This filing provides investors with an update on Evogene's financial performance for the second quarter of 2025, offering insights into the company's operational and financial health.
Risk Assessment
Risk Level: low — This is a routine financial results filing and does not introduce new risks.
Key Players & Entities
- Evogene Ltd. (company) — Registrant
- June 30, 2025 (date) — End of second quarter
- August 19, 2025 (date) — Date of announcement and filing
FAQ
What period do the financial results announced by Evogene Ltd. cover?
The financial results announced by Evogene Ltd. cover the second quarter ended June 30, 2025.
When did Evogene Ltd. announce its Q2 2025 financial results?
Evogene Ltd. announced its Q2 2025 financial results on August 19, 2025.
What form was used to file the financial results announcement?
The financial results announcement was filed using a Form 6-K.
Where is Evogene Ltd. headquartered?
Evogene Ltd.'s principal executive offices are located at 13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel.
Is Evogene Ltd. required to file annual reports under Form 20-F or 40-F?
Evogene Ltd. indicates it files annual reports under cover of Form 20-F.
Filing Stats: 375 words · 2 min read · ~1 pages · Grade level 10.8 · Accepted 2025-08-19 07:00:23
Filing Documents
- zk2533678.htm (6-K) — 12KB
- exhibit_99-1.htm (EX-99.1) — 601KB
- exhibit_99-2.htm (EX-99.2) — 24KB
- exhibit_99-2slide1.jpg (GRAPHIC) — 195KB
- exhibit_99-2slide2.jpg (GRAPHIC) — 269KB
- exhibit_99-2slide3.jpg (GRAPHIC) — 102KB
- exhibit_99-2slide4.jpg (GRAPHIC) — 195KB
- exhibit_99-2slide5.jpg (GRAPHIC) — 212KB
- exhibit_99-2slide6.jpg (GRAPHIC) — 103KB
- exhibit_99-2slide7.jpg (GRAPHIC) — 115KB
- exhibit_99-2slide8.jpg (GRAPHIC) — 85KB
- exhibit_99-2slide9.jpg (GRAPHIC) — 141KB
- exhibit_99-2slide10.jpg (GRAPHIC) — 102KB
- exhibit_99-2slide11.jpg (GRAPHIC) — 88KB
- exhibit_99-2slide12.jpg (GRAPHIC) — 86KB
- exhibit_99-2slide13.jpg (GRAPHIC) — 110KB
- exhibit_99-2slide14.jpg (GRAPHIC) — 103KB
- exhibit_99-2slide15.jpg (GRAPHIC) — 122KB
- image0.jpg (GRAPHIC) — 530KB
- 0001178913-25-002976.txt ( ) — 4163KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number: 001-36187 EVOGENE LTD. (Translation of Registrant's Name into English) 13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F CONTENTS On August 19, 2025, Evogene Ltd. (" Evogene ") announced its financial results for the second quarter ended June 30, 2025. A Copy of the press release announcing those results is furnished as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K (this " Form 6-K ") and is incorporated herein by reference. Evogene is holding a conference call on August 19, 2025 to discuss its quarterly results for the quarter ended June 30, 2025 and, in connection with that call, will make available to its investors a slide presentation to provide additional information regarding its business and its financial results. That slide presentation is attached as Exhibit 99.2 to this Form 6-K and is incorporated herein by reference. The GAAP financial statements tables contained in the press release attached to this Form 6-K are incorporated by reference in the registration statements on Form F-3 (Securities and Exchange Commission (" SEC ") File No. 333-277565), and Form S-8 (SEC File Nos. 333-259215, 333-193788, 333-201443, 333-203856, 333-286197 and 333-286197) of Evogene, and will be a part thereof from the date on which this Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: August 19, 2025 EVOGENE LTD. (Registrant) By: /s/ Yaron Eldad Yaron Eldad Chief Financial Officer EXHIBIT INDEX EXHIBIT NO. DESCRIPTION 99.1 Press Release: Evogene Reports Second Quarter 2025 Financial Results. 99.2 Slide presentation for conference call of Evogene held on August 19, 2025, discussing Evogene's quarterly financial results for the second quarter of 2025.